Plain-English translation of NCT03471117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a medication commonly used to treat type 2 diabetes, can help people with chronic kidney disease by reducing overactivity in their sympathetic nervous system (the part of your body that controls stress responses). Researchers believe that a buildup of a certain substance called ADMA may be driving excessive nerve activity in kidney disease patients, and this medication might help lower ADMA levels and calm this overactivity.
People with kidney disease have a higher risk of heart problems and death from cardiovascular complications than from kidney failure itself. One reason is that their sympathetic nervous system becomes overactive, which increases heart attack and stroke risk even when blood pressure is controlled with standard medications. This study is looking for a new way to address this overlooked problem.
You would take one pill by mouth every day for one month. The medication is provided free of charge. You may receive the active medication or a placebo (inactive pill) — neither you nor the researchers will know which one during the study. The study involves measurements of your nerve activity and blood markers before and after the treatment month to see if the medication reduces overactivity in your sympathetic nervous system.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States